Executive Summary
CMS proposed the biggest overhaul of TAVR coverage since the NCD's inception, floating Medicare coverage for asymptomatic patients — a move that would drag US practice toward the ESC 2025 posture on early intervention and pull the EARLY TAVR trial straight into the reimbursement code, which loosens the case for watchful waiting and tightens Edwards' near-term volume story just weeks before EW's July 23 earnings. Meanwhile an updated meta-analysis in Open Medicine of low/intermediate-risk RCTs (Rashid et al.) reaffirmed mortality parity between TAVI and SAVR but hardened the trade-off ledger: RR 2.19 for permanent pacemaker, RR 2.51 for reintervention, RR 4.77 for vascular complications. AI-ECG screening moved a step closer to real-world deployment as a composite LVSD/LVDD model detected structural heart disease with ~72–76% sensitivity across three multinational cohorts (NY Valves 2026), a potential upstream expansion of the referral funnel that CMS just widened downstream.
- CMS NCA reopens the TAVR coverage document and proposes covering asymptomatic severe AS, aligning US reimbursement with the EARLY TAVR era (Cardiovascular Business).
- Updated low/intermediate-risk RCT meta-analysis: TAVI mortality RR 0.88 (ns) but pacemaker RR 2.19, reintervention RR 2.51, vascular complications RR 4.77 (Rashid, Open Medicine).
- International guidelines review confirms age divergence: US favors SAVR <65, Europe SAVR <75, Asia-Pacific weights bicuspid/rheumatic anatomy heavily (Sharma, Rev Cardiovasc Med).
- Composite AI-ECG (LVSD+LVDD) detected prevalent SHD with 71.8–76.1% sensitivity and predicted new-onset SHD with 2.75–3.75-fold higher risk across ~124,000 patients (NY Valves 2026).
- First reported left-sided transvenous pacemaker through a TricValve bicaval prosthesis raises procedural questions for the growing heterotopic TR cohort (Spadaro, PACE).
What to watch: Edwards Lifesciences reports Q2 earnings July 23; commentary on the CMS asymptomatic coverage proposal and TAVR volume guidance will set the tone for the sector into the second half.
Aortic Valve (TAVR/TAVI)
CMS just moved US reimbursement in the direction of the ESC 2025 guideline, not the ACC/AHA 2020 one. The proposed NCA revision would extend Medicare coverage to asymptomatic severe AS (Cardiovascular Business) — a direct port of the EARLY TAVR signal into policy, well ahead of the next ACC/AHA update. ESC 2025 already made early intervention Class IIa for asymptomatic severe AS at low procedural risk; CMS is now asking whether US payment should follow. [NOTABLE]
The counterweight came from the low/intermediate-risk RCT meta-analysis in Open Medicine (Rashid et al., pooled RCTs 2017–2024, random-effects): mortality was numerically lower with TAVI (RR 0.88) but statistically indistinguishable from SAVR, while the trade-off burden was substantial — pacemaker RR 2.19, reintervention RR 2.51, new bundle branch block RR 2.10, vascular complications RR 4.77. Heterogeneity was high (I² 62–84%) for several endpoints. The narrative review by Sharma and colleagues reinforces the guideline divergence: US <65 favors SAVR; ESC pivots at 75 (and now 70 in the 2025 update); Asia-Pacific centers weigh bicuspid and rheumatic anatomy first. Expanding TAVR into asymptomatic and younger cohorts before robust 10-year durability data is exactly the exposure the surgical literature has been flagging.
Two Chinese single-center reports add texture. Lin et al. (N=111, retrospective) found functional MR improved in 53% of pure severe AR patients treated with TAVR — a hypothesis-generating signal, not a mandate, given retrospective design and short follow-up. Zhang et al. (N=122) identified preoperative main pulmonary artery diameter indexed to BSA as an independent predictor of 1-year mortality (HR 1.29). Both need prospective validation.
Mitral Valve
No dedicated primary or secondary MR trial data landed today, but the CMS TAVR pivot has an indirect mitral read-through: as more patients enter the structural pipeline via asymptomatic-AS screening, concomitant MR will be flagged earlier. The PSAR-TAVR functional MR analysis argues that in select patients with hypertension, lower LVEF, and higher baseline FMR, the aortic intervention alone drives meaningful MR reduction. That fits with what ACC/AHA 2020 and ESC 2025 already say: treat the upstream driver before adding a second procedure. TEER for ventricular secondary MR remains Class I in ESC 2025 (COAPT + RESHAPE-HF2) versus Class IIa in ACC/AHA 2020 — a gap the next US update will need to reconcile.
Tricuspid Valve
Two case reports today illustrate the procedural physics of heterotopic TR therapy, which the ESC 2025 elevated to Class IIa alongside transcatheter tricuspid repair and replacement. Lopiano et al. describe an 82-year-old whose iatrogenic ASD after AF ablation became hemodynamically significant only after bicaval valve implantation increased right atrial pressure and unmasked right-to-left shunting — reversed by percutaneous ASD closure. Spadaro et al. report the first left-sided transvenous pacemaker implanted through a TricValve bicaval prosthesis, threading a lead through nitinol stent struts. Both are N=1 but flag a real workflow problem: the heterotopic cohort is elderly, comorbid, and pacing-prone.
The surgical counterpoint remains ESC 2025 Class I for symptomatic severe primary TR (upgraded from IIa in ACC/AHA 2020) and Class IIa for symptomatic secondary TR with RV dilation. Contemporary isolated TV surgery outcomes at experienced centers are substantially better than the historic 8–20% mortality quoted when referral was late. An AI-driven Brazilian cohort of 803 severe TR patients reinforced the referral problem: 17.1% mortality, median EuroSCORE II 13.4%, median TRI-SCORE 7 — patients are still arriving too sick.
Surgical vs. Transcatheter Comparisons
Today's most rigorous comparison is the Rashid meta-analysis: TAVI and SAVR remain mortality-equivalent in low/intermediate-risk symptomatic severe AS, but the endpoint hierarchy that matters to durability — pacemaker (RR 2.19), reintervention (RR 2.51), vascular complications (RR 4.77) — all favor SAVR. TAVI wins on new-onset AF (RR 0.29). The Sharma review reinforces that observational US data show TAVR use rising in patients <65 despite guideline preference for surgery, with worse long-term mortality and higher pacemaker/readmission burdens in selected cohorts. The ESC's decision to move the TAVI-preferred threshold to 70 (from 75 in 2021) sits uneasily with these durability signals, especially for bicuspid anatomy where RCT evidence remains thin.
Preprint Highlights
Nothing structural-heart-relevant on bioRxiv today. The single preprint captured (Chai et al., lipid droplet biochemistry) is out of scope.
Device & Technology
The composite AI-ECG model presented at NY Valves 2026 is the more consequential technology story. Trained originally to detect LVSD (LVEF <40%) and LVDD (E/e' >15) separately, the combined signal identified prevalent SHD across ~124,000 patients from South Korea (ISH), Columbia, and the UK Biobank with 71.8–76.1% sensitivity, and identified individuals 2.75–3.75x more likely to develop incident SHD over 6 years. Sensitivity is "okay, not great," as discussant Niels van Royen noted, and the models were not trained on this composite endpoint. But as a triage tool feeding echocardiography — and, downstream, the structural clinic — it targets exactly the population CMS's asymptomatic proposal is designed to catch.
Regulatory & Policy
The CMS reopening of CAG-00430N is the single most important US policy event in structural heart this year. Extending coverage to asymptomatic severe AS operationalizes EARLY TAVR into practice — before ACC/AHA has formally moved. Expect commentary periods to focus on: (1) which asymptomatic populations qualify (EARLY TAVR criteria vs broader), (2) heart team documentation requirements, and (3) volume/outcomes thresholds. If finalized, this expands the eligible TAVR pool materially and blurs the ACC/AHA vs ESC divide on asymptomatic intervention.
Industry & Market
Edwards is the obvious beneficiary. Coverage expansion for asymptomatic AS aligns with Edwards' EARLY TAVR investment and its stated strategic focus on heart valve growth in the US. Anteris Technologies (AVR.AX) held onto most of a 6-month 85% rally despite a 3.5% pullback, riding DurAVR bicuspid-friendly positioning. Boston Scientific, down 54% over six months, sits at the bottom of the sector on Watchman/broader portfolio pressures — the TR device pipeline hasn't offset it yet.
Financial Analysis
The clinical-market pairing today is unusually clean: CMS proposes to reimburse a larger AS population; the meta-analytic evidence base underneath TAVR (mortality parity, higher pacemaker/reintervention/vascular burden) doesn't obviously support that expansion; Edwards' valuation (P/E trailing 51x, forward 27.8x) is priced for volume growth that the policy tailwind now supports even if the durability data is stretched. That's the tension. If CMS finalizes coverage for asymptomatic patients, near-term TAVR volumes rise materially. If ACC/AHA's next update lags CMS and tightens language around younger/asymptomatic populations pending durability data, the reimbursement–guideline gap becomes an operational risk for centers. Watch Edwards' July 23 call for guidance on how they're modeling the CMS proposal.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $93.64 (-1.24% daily); 6-month change +10.00%; near the top of a $74.66–$96.29 6-month range.
- Fundamentals: Market cap $53.9B; P/E trailing 51.17, forward 27.8; beta 0.85; 52-week range $72.30–$96.29.
- Analyst view: Consensus target $97.31 (range $84–$110, 26 analysts); recommendation: buy.
- Next earnings: July 23, 2026 (EPS est $0.74, revenue est $1.70B).
- Commentary: Pure-play TAVR name, most direct beneficiary of the CMS asymptomatic coverage proposal. Valuation is priced for continued double-digit valve growth; the Q2 call will be the first read on how management frames CMS and updated valve data.
Medtronic (MDT)
- Price: $82.01 (-2.17% daily); 6-month change -14.46%.
- Fundamentals: Market cap $105.0B; P/E trailing 22.47, forward 12.8; beta 0.58.
- Analyst view: Consensus target $97.73; recommendation: buy.
- Next earnings: August 18, 2026.
- Commentary: Evolut franchise participates in any TAVR expansion, though Medtronic's diversified portfolio dilutes single-catalyst leverage relative to EW.
Abbott (ABT)
- Price: $95.18 (-0.69% daily); 6-month change -23.55%.
- Fundamentals: Market cap $165.8B; P/E trailing 26.66, forward 15.72; beta 0.61.
- Analyst view: Consensus target $116.40; recommendation: buy.
- Next earnings: July 16, 2026.
- Commentary: MitraClip and TriClip revenue growth depends on TEER expansion in secondary MR (ESC Class I) and TR (ESC IIa). Broader Abbott weakness has masked the structural-heart contribution.
Boston Scientific (BSX)
- Price: $44.81 (-1.08% daily); 6-month change -54.11%.
- Fundamentals: Market cap $66.6B; P/E trailing 18.91, forward 12.08; beta 0.58.
- Analyst view: Consensus target $74.55; recommendation: strong buy.
- Next earnings: July 29, 2026.
- Commentary: Deep 6-month drawdown creates a re-rating setup if Q2 confirms structural-heart trajectory. ACURATE program remains a wild card.
Anteris Technologies (AVR.AX)
- Price: A$13.62 (-3.54% daily); 6-month change +85.56%.
- Fundamentals: Market cap A$1.3B; forward P/E -6.25 (unprofitable); beta 0.73.
- Analyst view: Sparse coverage (1 analyst, target A$13.00).
- Commentary: DurAVR THV positions Anteris in the bicuspid and durability-conscious segments where SAVR still dominates per current guidelines. Highly speculative; catalyst-driven.
Market outlook: Sector performance is bifurcating — pure-play valve exposure (EW, AVR.AX) is outperforming diversified medtech (MDT, ABT, BSX). CMS's asymptomatic coverage proposal is a genuine tailwind but arrives against a durability data set that hasn't fully validated the expansion. Earnings season starting July 16 (ABT), July 23 (EW), July 29 (BSX), and August 18 (MDT) will test whether policy optimism translates into guidance.
Clinical Trial Updates
Aortic
- NCT07689279 — Selection of Transcatheter Heart Valve With Intermediate Sizing (STHL-IS): Not yet recruiting, Phase 4, N=604, sponsored by AMC-UvA. Addresses annulus sizing decisions between adjacent valve sizes — a practical question that becomes more consequential as TAVR moves to younger patients where future valve-in-valve feasibility is a design constraint.
- NCT05172960 — ALLIANCE (SAPIEN X4): Recruiting, N=1234, Edwards Lifesciences. Next-generation balloon-expandable platform evaluation; watch for durability and paravalvular leak endpoints against the current SAPIEN 3 Ultra benchmark.
Landmark trials informing today's edition: EARLY TAVR (asymptomatic AS, driving the CMS proposal), PARTNER 3 and Evolut Low Risk (low-risk RCTs anchoring the meta-analysis), TRILUMINATE Pivotal and TRISCEND II (tricuspid transcatheter therapy underpinning ESC 2025 Class IIa), and COAPT/RESHAPE-HF2 (SMR TEER upgraded to ESC Class I).
Social & Conference Highlights
NY Valves 2026 remains the reference point for this cycle's data — the composite AI-ECG SHD detection study was the standout screening presentation. Expect continued discussion of how AI-ECG triage integrates with the newly widened CMS eligibility criteria.
Looking ahead: The CMS comment period will define the shape of asymptomatic TAVR coverage in the US, and Edwards' July 23 earnings call will be the first management commentary on the proposal. Expect both to reshape the next round of guideline drafting on both sides of the Atlantic.